Online citations, reference lists, and bibliographies.
← Back to Search

Claudin‐4 Immunohistochemistry Is Highly Effective In Distinguishing Adenocarcinoma From Malignant Mesothelioma In Effusion Cytology

V. Jo, E. Cibas, G. Pinkus
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Adenocarcinoma can be challenging to distinguish from malignant mesothelioma in effusions, and this distinction often requires ancillary studies and clinical correlation. Immunohistochemistry for claudin‐4, a tight‐junction‐associated protein, has recently been shown to distinguish adenocarcinoma from malignant mesothelioma, mostly in surgical specimens. Our aim was to validate and assess the immunoreactivity profile of claudin‐4 in a large series of malignant effusions.
This paper references
10.1155/2010/541957
Claudin Family of Proteins and Cancer: An Overview
A. B. Singh (2010)
10.1016/J.CANCERGENCYTO.2004.08.005
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma.
A. Sandberg (2004)
10.4103/1742-6413.99170
Parakeratotic-like cells in effusions — A clue to diagnosis of malignant mesothelioma
L. Gao (2012)
10.1038/modpathol.3800544
The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study
N. Ordóñez (2006)
10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
10.1097/PAS.0b013e318216c112
A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors
Anna R. Laury (2011)
10.1038/modpathol.2013.34
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma
N. Ordóñez (2013)
10.1002/DC.2840110309
Markers for metastatic adenocarcinoma in serous effusion specimens
P. Shield (1994)
10.1002/1097-0142(20000625)90:3<194::AID-CNCR8>3.0.CO;2-K
Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions
D. Chhieng (2000)
10.1309/AJCP0B3YJBXWXJII
Value of claudin-4 immunostaining in the diagnosis of mesothelioma.
N. Ordóñez (2013)
Calretinin staining pattern
DC Chhieng
10.1111/j.1399-0004.2010.01397.x
Claudins: unlocking the code to tight junction function during embryogenesis and in disease
I. Gupta (2010)
10.1038/MODPATHOL.2008.149
The diagnostic and prognostic utility of claudin expression in renal cell neoplasms
Mirna Lechpammer (2009)
10.1111/j.1699-0463.1989.tb00475.x
Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions
A. F. Lauritzen (1989)
10.1002/dc.21380
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions
S. Lonardi (2011)
10.1136/jcp.2005.028589
Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
Y. Soini (2006)
10.1097/01.pai.0000213148.62525.9a
Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma
A. Marchevsky (2007)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
10.1002/DC.2028
Comparison of antibodies to HBME‐1 and calretinin for the detection of mesothelial cells in effusion cytology
P. Fetsch (2001)
10.1002/cncy.20036
Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma
Rachel E. Factor (2009)
10.1111/j.1365-2303.2007.00482.x
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions
P. Shield (2008)
10.1002/DC.2840100207
Monoclonal antibody Ber‐EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens
B. Maguire (1994)
10.1159/000333982
Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
M. E. Bailey (1996)
10.1007/s00428-007-0448-x
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
F. Facchetti (2007)
10.1038/modpathol.2012.187
Claudin Expression in High Grade Invasive Ductal Carcinoma of the Breast: Correlation with the Molecular Subtype
Shaolei Lu (2013)
Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
D. Frisman (1993)
10.1016/S0165-4608(01)00432-0
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma.
A. Sandberg (2001)
10.1097/00129039-200206000-00001
Thyroid Transcription Factor-1: A Review
S. Lau (2002)
10.1038/modpathol.2012.200
Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas
N. Ordóñez (2013)
10.1186/gb-2009-10-8-235
The claudins
M. Lal-Nag (2009)
10.1002/DC.20747
Utility of WT‐1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions
Robert T. Pu (2008)
10.1043/1543-2165(2008)132[23:CMVBHU]2.0.CO;2
Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Virganeyce Lyons-Boudreaux (2008)
10.1097/00000478-200303000-00003
CDX2, a Highly Sensitive and Specific Marker of Adenocarcinomas of Intestinal Origin: An Immunohistochemical Survey of 476 Primary and Metastatic Carcinomas
Robert W Werling (2003)
10.1097/PAS.0b013e3181da7687
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Anna R. Laury (2010)
10.1016/S0046-8177(87)80196-X
The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
E. Cibas (1987)
10.1245/s10434-011-1970-2
Claudin-4 Expression Predicts Survival in Pancreatic Ductal Adenocarcinoma
K. Tsutsumi (2011)
10.1093/AJCP/109.1.85
Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
N. Ordóñez (1998)
10.1111/j.1365-2559.2007.02743.x
Claudin‐4 in mesothelioma diagnosis
F. Facchetti (2007)



This paper is referenced by
10.1007/s00428-017-2273-1
The diagnostic role of PTEN and ARID1A in serous effusions
B. Davidson (2017)
10.1016/j.jasc.2019.12.003
Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
Ami Patel (2020)
10.1016/j.humpath.2020.04.005
Claudin-4 Shows Superior Specificity for Mesothelioma vs Non-Small Cell Lung Carcinoma Compared to MOC-31 and Ber-EP4.
Julia R Naso (2020)
10.1186/s12885-020-6670-5
P16 as a marker of carcinoma in effusions and peritoneal washing
Fabiana Pirani Carneiro (2020)
10.1017/9781316402009.006
Cytology of Pleural and Peritoneal Lesions
Shikha Bose (2018)
10.4103/EGJP.EGJP_27_19
Reliability of p-16, calretinin, and claudin-4 immunocytochemistry in diagnostic verification of effusion cytology
Eman S. Abusinna (2019)
10.1016/j.humpath.2016.08.005
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
B. Davidson (2016)
Biomarkers for pancreatic cancer : identification, validation and clinical application
Asif Ali (2015)
10.1002/cncy.22255
Serous cavity fluids: Momentum, molecules, markers… and more!
Momin T Siddiqui (2020)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.3389/fphys.2017.00156
Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status
E. Rouka (2017)
BIBLIOGRAPHIC REVIEW July 2016 Third Consensus Conference on Malignant Pleural Mesothelioma: State-of-the-art and recommendations
(2016)
10.1111/resp.13539
Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions
J. M. Porcel (2019)
10.1038/srep09507
Diagnostic Accuracy of Calretinin for Malignant Mesothelioma in Serous Effusions: a Meta-analysis
Diandian Li (2015)
10.1016/j.prp.2019.152462
Signet ring cell mesothelioma; A diagnostic challenge.
Hui Wang (2019)
10.1097/PAI.0000000000000357
Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement
Asif Ali (2017)
10.1159/000447008
Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks
N. I. Kim (2016)
10.1016/B978-0-323-44227-5.00012-0
Chapter 12 – Pericardial Disease and Effusion
D. Lotan (2016)
10.1159/000501406
Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology
Piao Piao Ang (2019)
10.1111/cyt.12765
Claudin‐4 immunohistochemistry is a useful pan‐carcinoma marker for serous effusion specimens
Melissa Vojtek (2019)
10.1002/dc.24315
A case of malignant mesothelioma pleural effusion with MOC‐31, BerEP4, and calretinin expression
Po Zhao (2019)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1186/s12885-018-4141-z
High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
A. Jääskeläinen (2018)
10.3892/OL.2019.10468
Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash.
F. Carneiro (2019)
10.1586/14779072.2015.1025754
2015 update on the diagnosis and management of neoplastic pericardial disease
C. Lestuzzi (2015)
10.1002/dc.23476
Immunocytochemical utility of claudin‐4 versus those of Ber‐EP4 and MOC‐31 in effusion cytology
T. Oda (2016)
10.1016/j.humpath.2018.05.012
The diagnostic role of BAP1 in serous effusions.
B. Davidson (2018)
10.1097/PAP.0000000000000256
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin
A. Bellizzi (2020)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1002/cncy.22021
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology
K. Sundling (2018)
Semantic Scholar Logo Some data provided by SemanticScholar